Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 7Completed 5Withdrawn 2Unknown 2Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1Hematologic Neoplasms 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × ceritinib × Clear all
NCT02289144 2019-07-30

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

University of Texas Southwestern Medical Center

Phase 2 Withdrawn
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT02343679 2017-02-01

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

Duke University

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡